Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3015 SEK | +3.97% | -39.40% | -96.98% |
Mar. 18 | Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index | CI |
Feb. 26 | Transcript : Xbrane Biopharma AB, 2023 Earnings Call, Feb 26, 2024 |
Sales 2023 | 239M 22.35M | Sales 2024 * | 372M 34.82M | Capitalization | 8.65M 809K |
---|---|---|---|---|---|
Net income 2023 | -388M -36.32M | Net income 2024 * | -101M -9.45M | EV / Sales 2023 | 1.25 x |
Net Debt 2023 * | 164M 15.31M | Net cash position 2024 * | 138M 12.96M | EV / Sales 2024 * | -0.35 x |
P/E ratio 2023 |
-0.74
x | P/E ratio 2024 * |
-2.9
x | Employees | 93 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 99.23% |
Latest transcript on Xbrane Biopharma AB
1 day | +5.69% | ||
1 week | -51.43% | ||
Current month | -60.14% | ||
1 month | -45.27% | ||
3 months | -96.78% | ||
6 months | -98.86% | ||
Current year | -96.94% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 14-12-31 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 21-01-10 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 17-10-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 14-12-31 | |
Director/Board Member | 70 | 14-12-31 | |
Director/Board Member | 53 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.3015 | +3.97% | 42 905 004 |
24-03-27 | 0.29 | +11.54% | 42,937,050 |
24-03-26 | 0.26 | -2.07% | 30,914,020 |
24-03-25 | 0.2655 | -46.47% | 89,924,220 |
24-03-22 | 0.496 | -21.39% | 14,555,870 |
Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:21 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.94% | 814K | |
+9.16% | 45.97B | |
+54.37% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |